GlucoTrack faces Nasdaq delisting over minimum bid price deficiency

• GlucoTrack received Nasdaq staff determination May 11, 2026, citing noncompliance with Listing Rule 5550(a)(2) minimum $1 bid price requirement, triggering a delisting decision for its Nasdaq Capital Market securities.
• Hearing request due by May 18, 2026; a timely request would stay further delisting action while GlucoTrack presents a plan to regain compliance.
• Nasdaq issued a second notice May 15, 2026, flagging failure to meet Listing Rule 5550(b)(1) $2.5 million minimum stockholders’ equity threshold, creating an additional basis for delisting.
• Hearings Panel will weigh both deficiencies when deciding continued listing; outcome remains uncertain.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GlucoTrack Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-023889), on May 15, 2026, and is solely responsible for the information contained therein.